Horizon Pharma Inc. (NASDAQ:HZNP) Receives Average Rating of “Buy” from Analysts
Horizon Pharma Inc. (NASDAQ:HZNP) has been assigned an average recommendation of “Buy” from the sixteen ratings firms that are currently covering the stock. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating, eleven have issued a buy rating and one has issued a strong buy rating on the company. The average 12 month target price among brokers that have covered the stock in the last year is $31.56.
A number of equities research analysts have commented on HZNP shares. Vetr upgraded Horizon Pharma from a “buy” rating to a “strong-buy” rating in a research report on Monday. Stifel Nicolaus restated a “buy” rating and set a $45.00 price objective on shares of Horizon Pharma in a research report on Wednesday, July 6th. Guggenheim restated a “buy” rating and set a $30.00 price objective on shares of Horizon Pharma in a research report on Tuesday, August 23rd. Morgan Stanley upgraded Horizon Pharma from an “underweight” rating to an “equal weight” rating and set a $24.00 price objective for the company in a research report on Monday, July 11th. Finally, Brean Capital restated a “buy” rating and set a $30.00 price objective on shares of Horizon Pharma in a research report on Thursday, July 14th.
In related news, EVP Jeffrey W. Sherman sold 2,900 shares of the firm’s stock in a transaction that occurred on Tuesday, August 2nd. The stock was sold at an average price of $20.00, for a total value of $58,000.00. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 2.10% of the stock is owned by corporate insiders.
Hedge funds and other institutional investors have recently modified their holdings of the stock. Virginia Retirement System bought a new position in shares of Horizon Pharma during the first quarter worth $282,000. Algert Global LLC increased its position in shares of Horizon Pharma by 57.3% in the first quarter. Algert Global LLC now owns 20,872 shares of the biopharmaceutical company’s stock worth $346,000 after buying an additional 7,602 shares during the last quarter. Franklin Resources Inc. increased its position in shares of Horizon Pharma by 5,195.9% in the first quarter. Franklin Resources Inc. now owns 1,276,730 shares of the biopharmaceutical company’s stock worth $21,155,000 after buying an additional 1,252,622 shares during the last quarter. BlackRock Group LTD increased its position in shares of Horizon Pharma by 21.0% in the first quarter. BlackRock Group LTD now owns 100,919 shares of the biopharmaceutical company’s stock worth $1,672,000 after buying an additional 17,505 shares during the last quarter. Finally, BlackRock Fund Advisors increased its position in shares of Horizon Pharma by 7.6% in the first quarter. BlackRock Fund Advisors now owns 2,937,687 shares of the biopharmaceutical company’s stock worth $48,677,000 after buying an additional 208,391 shares during the last quarter. 85.25% of the stock is currently owned by institutional investors and hedge funds.
Horizon Pharma (NASDAQ:HZNP) traded down 1.767% on Friday, hitting $18.625. 809,945 shares of the stock traded hands. The company’s 50 day moving average price is $19.27 and its 200-day moving average price is $17.78. Horizon Pharma has a 52-week low of $12.86 and a 52-week high of $23.70. The stock’s market cap is $3.00 billion.
Horizon Pharma (NASDAQ:HZNP) last announced its quarterly earnings data on Monday, August 8th. The biopharmaceutical company reported $0.62 EPS for the quarter, topping the Zacks’ consensus estimate of $0.50 by $0.12. Horizon Pharma had a positive return on equity of 23.46% and a negative net margin of 0.34%. The firm earned $257.40 million during the quarter, compared to analyst estimates of $235.43 million. During the same period last year, the company posted $0.39 EPS. The business’s quarterly revenue was up 48.9% compared to the same quarter last year. On average, analysts forecast that Horizon Pharma will post $2.15 earnings per share for the current fiscal year.
About Horizon Pharma
Horizon Pharma plc, formerly Vidara Therapeutics International Public Limited Company, is a biopharmaceutical company. The Company is focused on identifying, developing, acquiring or in-licensing and commercializing differentiated products. It markets approximately nine medicines through its orphan, primary care and rheumatology business units.
Receive News & Stock Ratings for Horizon Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Pharma Inc. and related stocks with our FREE daily email newsletter.